









ARTICLE

A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies

Kevin ten Haaf , Mehrad Bastani, Pianpian Cao , Jihyoun Jeon ,
Iakovos Toumazis , Summer S. Han, Sylvia K. Plevritis, Erik F. Blom,
Chung Yin Kong , Martin C. Tammemägi, Eric J. Feuer , Rafael Meza *,
Harry J. de Koning *

See the Notes section for the full list of authors' affiliations.

*All authors contributed equally to this work.

Correspondence to: Kevin ten Haaf, PhD, Erasmus MC, Department of Public Health, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, the Netherlands (e-mail: k.tenhaaf@erasmusmc.nl).

Abstract

Background: Risk-prediction models have been proposed to select individuals for lung cancer screening. However, their long-term effects are uncertain. This study evaluates long-term benefits and harms of risk-based screening compared with current United States Preventive Services Task Force (USPSTF) recommendations.

Methods: Four independent natural history models were used to perform a comparative modeling study evaluating long-term benefits and harms of selecting individuals for lung cancer screening through risk-prediction models. In total, 363 risk-based screening strategies varying by screening starting and stopping age, risk-prediction model used for eligibility (Bach, PLCOm2012, or Lung Cancer Death Risk Assessment Tool [LCDRAT]), and risk threshold were evaluated for a 1950 US birth cohort. Among the evaluated outcomes were percentage of individuals ever screened, screens required, lung cancer deaths averted, life-years gained, and overdiagnosis.

Results: Risk-based screening strategies requiring similar screens among individuals ages 55–80 years as the USPSTF criteria (corresponding risk thresholds: Bach = 2.8%; PLCOm2012 = 1.7%; LCDRAT = 1.7%) averted considerably more lung cancer deaths (Bach = 693; PLCOm2012 = 698; LCDRAT = 696; USPSTF = 613). However, life-years gained were only modestly higher (Bach = 8660; PLCOm2012 = 8862; LCDRAT = 8631; USPSTF = 8590), and risk-based strategies had more overdiagnosed cases (Bach = 149; PLCOm2012 = 147; LCDRAT = 150; USPSTF = 115). Sensitivity analyses suggest excluding individuals with limited life expectancies (<5 years) from screening retains the life-years gained by risk-based screening, while reducing overdiagnosis by more than 65.3%.

Conclusions: Risk-based lung cancer screening strategies prevent considerably more lung cancer deaths than current recommendations do. However, they yield modest additional life-years and increased overdiagnosis because of predominantly selecting older individuals. Efficient implementation of risk-based lung cancer screening requires careful consideration of life expectancy for determining optimal individual stopping ages.

The National Lung Screening Trial (NLST) demonstrated that computed tomography (CT) screening reduces lung cancer mortality (1). Consequently, the United States Preventive Services Task Force (USPSTF) recommended lung cancer screening (2).

Current guidelines propose screening eligibility using age and smoking-related criteria, through combinations of accumulated pack-years and years since smoking cessation ("pack-year criteria") (2). Notably, the USPSTF recommends annual

Received: March 25, 2019; Revised: June 27, 2019; Accepted: August 14, 2019

© The Author(s) 2019. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

screening between ages 55 and 80 years for current and former smokers (quit <15 years) who smoked 30 or more pack-years (“USPSTF criteria”).

Individual risk assessment using established lung cancer risk-prediction models has suggested superiority over pack-year criteria in identifying those most likely to benefit from screening (3–6). This is partly due to these models incorporating smoking history in greater detail than pack-years and considering risk factors such as chronic obstructive pulmonary disease (COPD). Consequently, some guidelines recommend risk assessment through these models to supplement pack-year criteria (7).

The Dutch-Belgian Lung Cancer Screening Trial (NELSON) recently announced results confirming that CT screening reduces lung cancer mortality (8). Consequently, countries worldwide are considering implementing lung cancer screening. Experts recommend future programs determine screening eligibility through risk-stratification (9).

However, little is known about the long-term benefits and harms of risk-based lung cancer screening (3–5,10). Trials selecting participants through risk-prediction models show high lung cancer detection rates, suggesting successful identification and enrollment of high-risk individuals, but long-term outcomes are uncertain (11,12). Furthermore, these studies assessed risk at a single time point; generally randomization. But, risk varies over time because of aging, changes in smoking behavior, and other risk factors. Furthermore, high-risk individuals have increased non-lung cancer mortality risks, and thus shorter life expectancies, potentially affecting long-term screening benefits and harms (13–16). Therefore, risk-prediction models may perform dissimilarly in population-based screening programs compared with retrospective studies. To our knowledge, previous studies evaluating risk-based screening considered limited strategies, focused solely on benefits, and did not consider the general population or evaluate effectiveness over lifetime periods (6,10,15,17,18).

Natural history models of the Cancer Intervention and Surveillance Modeling Network (CISNET) previously informed the USPSTF on long-term benefits and harms of lung cancer screening strategies with pack-year criteria (19). In contrast to risk-prediction models, natural history models simulate an individual’s entire life history, accounting for lifetime variations in lung cancer and smoking-related mortality risk. This allows natural history models to evaluate differences in life-years gained and overdiagnosis (screen detection of cancers that would not have been diagnosed in the absence of screening) across different risk profiles. This study evaluates long-term benefits and harms of lung cancer screening strategies selecting individuals through risk-prediction models in the general population, through a comparative modeling analysis using four CISNET natural history models.

Methods

Risk-Prediction Models

CISNET previously evaluated nine risk-prediction models for lung cancer incidence and mortality (5). The Bach, PLCOm2012, and Two-Stage Clonal Expansion (TSCE) incidence models had the best performance across investigated aspects (calibration, discrimination, and clinical usefulness) (3,5,20,21). However, TSCE is primarily meant to describe lung carcinogenesis within a biological framework, whereas Bach and PLCOm2012 can be easily

implemented in clinical settings. Additionally, the Lung Cancer Death Risk Assessment Tool (LCDRAT) was considered (10). Therefore, analyses were restricted to Bach/PLCOm2012/LCDRAT (Supplementary Methods and Supplementary Tables 1–5 and Supplementary Figure 1, available online). PLCOm2012 was calibrated to a 6-year timeframe, whereas Bach and LCDRAT can be applied to any timeframe (3,10,20). Therefore, 6-year timeframes were chosen for comparability.

Simulated Population

The Smoking History Generator (SHG), developed using 1965–2009 US-representative National Health Interview Survey data, was used to simulate smoking histories for a 1950 US cohort (13,22,23). This population, currently ages 68–69 years, represents the midpoint between recommended screening starting and stopping ages (55 and 80 years). Each simulated smoking history consists of whether and when the person initiates and ceases smoking, average number of cigarettes smoked per day by age, and the age of death from non-lung cancer causes (accounting for the effects of smoking behavior on mortality).

For each simulated individual, model-specific 6-year lung cancer incidence/mortality risks were estimated by age (Supplementary Table 6 and Supplementary Figure 2, available online). Because the SHG does not simulate nonsmoking covariates, risk-prediction models were applied using only age, sex, and smoking history (Supplementary Methods, available online). “Never-smokers” were not considered for screening because the risk-prediction models are not applicable to them. Furthermore, never-smokers are unlikely to attain risks at which screening becomes beneficial (24,25).

Risk Thresholds

Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) data were previously used to assess the net benefit (better ratios of benefits to harms) of Bach and PLCOm2012 over that of the USPSTF criteria (5). Both had wide ranges of risk thresholds yielding positive net benefits for 6-year lung cancer incidence in the PLCO control-arm ever-smokers (Bach = 0.2–8.9%; PLCOm2012 = 0.1–11.0%) (5).

The Supplementary Methods, Supplementary Table 7, and Supplementary Figure 3 (available online) describe how risk thresholds with positive net benefits can inefficiently select individuals for screening. Furthermore, higher risk thresholds may improve screening efficiency (screens required to detect one cancer), but reduce screening effectiveness (achievable mortality reduction).

To capture trade-offs between screening efficiency and effectiveness, evaluated risk thresholds were chosen based on sensitivity (eg, the number of individuals developing clinical lung cancer within 6 years among those whose estimated risk exceeds the corresponding risk threshold divided by the total number of individuals who develop clinical lung cancer within 6 years). Risk thresholds yielding sensitivities for lung cancer incidence between 50% and 90% in the PLCO control-arm ever-smokers were further evaluated. Corresponding risk thresholds were 0.93–3.55% (Bach) and 0.94–3.30% (PLCOm2012). Therefore, risk thresholds between 0.9% and 3.6% were evaluated, with absolute increments of 0.1%. Corresponding LCDRAT risk thresholds for lung cancer mortality were 0.65%–2.13%.

Additionally, we considered risk thresholds, selecting similar proportions of individuals (Bach = 1.59%; PLCOm2012 = 1.36%;

LCDRAT = 0.96%) or yielding similar sensitivities (Bach = 1.91%; PLCOm2012 = 1.83%; lung cancer mortality sensitivity [LCDRAT] = 1.34%) as the USPSTF criteria in PLCO control-arm ever-smokers (screen-eligible proportion = 39.0%, sensitivity = 75.3%). The risk thresholds corresponding to these outcomes differ across risk-prediction models because of differences in absolute risk estimates, indicating that risk model-specific risk thresholds should be used (5,26). [Supplementary Figure 4](#) (available online) gives risk-prediction model-specific overviews of sensitivity by risk threshold, whereas [Supplementary Figure 5](#) (available online) gives an overview of the proportion of screening-eligible individuals by risk threshold.

However, risk thresholds performing well within retrospective analyses of trials and/or cohorts may not necessarily yield similar performances in population-based programs. Therefore, risk thresholds yielding similar metrics as the USPSTF criteria's in the 1950 birth cohort (eg, deaths averted and life-years gained) were identified.

Natural History Models

Four CISNET natural history models were used in these analyses (27–33). All models were calibrated to individual-level data from NLST and PLCO, and we evaluated the same individual risk profiles generated by the SHG. The [Supplementary Methods](#), [Supplementary Figure 6](#), and [Supplementary Table 8](#) (available online) detail the characteristics of the natural history models.

Evaluated Screening Strategies

In total, 363 screening strategies were evaluated, each considering different combinations of screening starting and stopping ages, risk-prediction model used to estimate age-specific lung cancer incidence risk, and risk threshold for screening eligibility ([Box 1](#)). Upper bounds on screening stopping ages were enforced, as otherwise-eligible individuals would continue screening at ages with limited life expectancy. Lower bounds on screening starting age were enforced because the risk-prediction models were developed in populations consisting of individuals older than 45 years and may be unsuitable for younger individuals (3,20). At each age, a person's screening eligibility was determined (ie, whether the person's estimated risk at that age exceeded the risk threshold). Screening eligibility was assumed to be free of misclassification error (ie, risk at each age was correctly estimated, and ineligible individuals were not screened). In total, 120 screening strategies were considered per risk-prediction model. In addition, three screening strategies were used to evaluate the USPSTF criteria at different stopping ages. Perfect screening adherence was assumed. For each strategy, the following outcomes were evaluated: lung cancer deaths averted, life-years gained, proportion of individuals ever screening eligible, computed tomography screens required, and overdiagnosis (both the absolute number of overdiagnosed cases and percentage of screen-detected cases that is overdiagnosed, ie, $\frac{\text{number of overdiagnosed cases}}{\text{number of screen-detected cases}} * 100\%$). Screening outcomes were counted from ages 45–100 years (maximum age in all models). All outcomes were compared with no-screening results, and standardized to the number of individuals alive at age 45 years. Results were summarized as means across CISNET models, along with the lower and upper ranges across models (CISNET model range [CMR]). Two sensitivity analyses were performed. The first considered hypothetical perfect life expectancy assessments, excluding individuals from further screening when non-

Box 1. Overview of evaluated screening strategies

Strategy characteristics	Considered values
Age to start screening, y	45*, 55
Age to stop screening, y	75, 77, 80
Screening interval	Annual
Risk-based criteria	Considered values
Evaluated risk-prediction models	Bach, PLCOm2012, LCDRAT
Evaluated risk thresholds	0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, †Risk threshold that yielded a similar sensitivity for ever-smokers in the PLCO control arm as the USPSTF criteria (one for each risk-prediction model) ‡Risk thresholds that selected a similar proportion of ever-smokers for screening in the PLCO control arm as the USPSTF criteria (one for each risk-prediction model)
Non-risk-based strategies	Description
USPSTF-smoking eligibility criteria	Annual screening for individuals who smoked at least 30 pack-years and currently smoke or quit less than 15 y ago The USPSTF criteria was evaluated for screening between age ranges 55–75, 55–77, and 55–80 y

*Considered only for risk-based strategies that stop screening at age 80 y.

†Corresponding risk thresholds: PLCOm2012 = 1.83%; Bach = 1.91%; LCDRAT = 1.34%.

‡Corresponding risk thresholds: PLCOm2012 = 1.36%; Bach = 1.59%; LCDRAT = 0.96%.

LCDRAT = Lung Cancer Death Risk Assessment Tool; PLCO = Prostate Lung, Colorectal, and Ovarian Cancer Screening Trial, USPSTF: United States Preventive Services Task Force.

lung cancer death occurred within 5 years. The second considered a 1960 birth cohort, representing smoking patterns and life expectancies that are more contemporary.

Results

Overall Results

At the first age individuals become eligible for screening because of their risk exceeding the risk threshold, their risk is generally close to the considered risk threshold. However, the average risk of the population eligible for screening was substantially higher than the risk threshold required for screening

Screens and lung cancer deaths averted for risk-based screening policies between ages 55 and 80 years compared to the USPSTF criteria




Figure 1. Number of CT screens and lung cancer deaths averted for risk-based screening strategies screening between ages 55 and 80 years compared with the USPSTF criteria (mean results across the four CISNET models). Risk thresholds corresponding to strategies that yield a similar number of lung cancer deaths averted as the USPSTF criteria: Bach model = 3.4%; PLCom2012 model = 2.2%; LCDRAT model = 2.1%. CT = computed tomography; LCDRAT = Lung Cancer Death Risk Assessment Tool; USPSTF = United States Preventive Services Task Force.

eligibility for each risk-prediction model at each time-point (Supplementary Figure 7, available online). However, screening eligibility decreased for increasing risk thresholds and younger screening stopping ages (Supplementary Figure 8, available online). Screening eligibility was higher for the Bach-based strategy than for PLCom2012-based and LCDRAT-based strategies at each risk threshold. Screening eligibility increased with age for all risk-prediction models independently of risk threshold (Supplementary Figure 9, available online). For the USPSTF criteria, screening eligibility decreased with age because of increasing numbers of previously eligible individuals having quit smoking 15 or more years prior.

Figures 1 and 2 compare risk-based-strategies screening between ages 55 and 80 years to the USPSTF criteria. The Bach-based strategy required more screens than the PLCom2012-based and LCDRAT-based strategies at each risk threshold, but averted more deaths and yielded more life-years. However, risk-based strategies requiring similar screens yielded consistent deaths averted and life-years gained. For all CISNET models, risk-based strategies more efficiently averted lung cancer deaths (Figure 1; Supplementary Figure 10, available online) and life-years gained (Figure 2; Supplementary Figure 11, available online) than the USPSTF criteria did. However, whereas increases in deaths averted were considerable, gains in life-years were modest. Similar results were found for screening stopping ages 77 and 75 years (data not shown). Tables 1–3 summarize benefits and harms for risk-based-strategies screening between ages 55 and 80 years corresponding to selected outcomes, described in the following paragraphs.

Screening Eligibility

Risk-based-strategies screening between ages 55 and 80 years with risk thresholds selecting similar proportions of PLCO control-arm ever-smokers as the USPSTF criteria (Bach = 1.59%; PLCom2012 = 1.36%; LCDRAT = 0.96%) selected considerably more individuals in the 1950 birth cohort (Bach = 32.0%; PLCom2012 = 26.0%; LCDRAT = 33.4%; USPSTF = 19.9%). These

strategies averted 25.2–38.0% more lung cancer deaths (CMR = 23.2–49.1%) and yielded 17.0–30.3% more life-years (CMR = 11.7–37.9%) than the USPSTF criteria did, but required 23.8–58.6% more screens (CMR = 21.4–60.2%).

Sensitivity

Risk-based-strategies screening between ages 55 and 80 years with risk thresholds yielding a similar sensitivity as the USPSTF criteria's in PLCO control-arm ever-smokers (Bach = 1.91%; PLCom2012 = 1.83%; LCDRAT = 1.34%) differed in effectiveness and efficiency. The Bach-based strategy required 40.2% more screens (CMR = 38.9–41.5%) than the USPSTF criteria did, but averted 31.8% more deaths (CMR = 28.8–37.6%) and yielded 22.6% more life-years (CMR = 19.9–27.5%). However, the USPSTF criteria required 533 screens per lung cancer death averted and 38 screens per life year gained, whereas the Bach-based strategy required 567 (+6.4%; CMR = +1.1% to +9.2%) and 43 (+14.3%; CMR = +10.6% to +16.2%), respectively. The PLCom2012-based strategy required 6.0% fewer screens (CMR = 5.0–7.5%) than the USPSTF criteria did, while averting 10.8% more deaths (CMR: 2.3–15.0%) and yielding similar life-years (-0.1%; CMR = -9.9% to +4.3%). Overall, the PLCom2012-based strategy was more efficient than the USPSTF criteria was, requiring 452 screens per lung cancer death averted (-15.2%; CMR = -18.1% to -8.1%) and 36 screens per life year gained (-5.9%; CMR = -9.7% to +4.4%). The LCDRAT strategy required more screens than the USPSTF criteria did (+20.7%; CMR = 18.6–22.0%), but it averted more deaths (+24.9%; CMR = 22.6–32.8%) and yielded more life-years (+13.3%; CMR = 10.3–17.3%). The LCDRAT strategy was more efficient than the USPSTF criteria was regarding screens per lung cancer death averted (-3.4%; CMR = -8.5% to -0.5%), but it required more screens per life-year gained (+6.5%; CMR = 3.6–8.6%).

CT Screens

Risk-based-strategies screening between ages 55 and 80 years requiring similar CT screens as the USPSTF criteria did (corresponding risk thresholds: Bach = 2.8%; PLCom2012 = 1.7%;

Screens and life-years gained for risk-based screening policies between ages 55 and 80 years compared to the USPSTF criteria




Figure 2. Number of CT screens and life-years gained for risk-based screening strategies screening between ages 55 and 80 years compared with the USPSTF criteria (mean results across the four CISNET models). Risk thresholds corresponding to strategies that yield a similar number of life-years gained as the USPSTF criteria: Bach model = 2.8%; PLCOm2012 model = 1.83%; LCDRAT model = 1.7%. CT = computed tomography; LCDRAT = Lung Cancer Death Risk Assessment Tool; USPSTF = United States Preventive Services Task Force.

LCDRAT = 1.7%) averted 13.1–13.9% (CMR = 7.3–19.5%) more lung cancer deaths (USPSTF criteria = 613; Bach = 693; PLCOm2012 = 698; LCDRAT = 696). However, life-years gained was only modestly higher: 0.5–3.2% more (CMR = –6.0% to +8.9%; USPSTF criteria = 8590; Bach = 8660; PLCOm2012 = 8862; LCDRAT = 8631). These strategies more efficiently reduced lung cancer mortality than the USPSTF criteria did, requiring 466–472 screens per death averted (–11.5% to –12.5% compared with the USPSTF criteria; CMR = –16.4% to –6.0%). However, they were only slightly more efficient with regard to life-years gained, requiring 37–38 screens per life year gained (–0.9% to –2.2% compared with the USPSTF criteria; CMR = –6.9% to +6.0%).

Lung Cancer Deaths Averted

Risk-based-strategies screening between ages 55 and 80 years averting similar deaths as the USPSTF criteria's (corresponding risk thresholds: Bach = 3.4%; PLCOm2012 = 2.2%; LCDRAT = 2.1%) required 20.5–22.7% fewer screens (CMR = 19.7–24.0%). Therefore, these strategies were more efficient than the USPSTF criteria was, requiring 409–419 screens per lung cancer death averted (CMR = 293–868). However, despite averting similar lung cancer deaths, they yielded 12.1–12.4 life-years per death averted (CMR = 11.4–13.3) compared with 14.0 for the USPSTF criteria (CMR = 13.0–15.3). Consequently, they yielded 12.5–13.4% fewer life-years (CMR = 8.0–24.0%).

Life-Years Gained

Risk-based-strategies screening between ages 55 and 80 years yielding similar life-years gained as the USPSTF criteria's (corresponding risk thresholds: Bach = 2.8%; PLCOm2012 = 1.83%; LCDRAT = 1.7%) required 0.5–6.0% fewer screens (CMR = +0.6 to –7.5%) and averted 10.8–13.5% more deaths (CMR = 2.3–19.5%). Consequently, these strategies were slightly more efficient, requiring 36–38 screens per life-year gained (–0.9% to –5.9%

compared with the USPSTF criteria; CMR: –9.7% to +6.0%). However, they yielded only 12.4–12.6 life-years per lung cancer death averted (CMR = 11.8–13.6). Furthermore, these risk-based strategies had 25.9–30.1% (CMR = 15.0–33.0%) more overdiagnosed cases than the USPSTF criteria did.

Overdiagnosis

All risk-based-strategies screening between ages 55 and 80 years yielded higher screen-detected overdiagnosis rates than the USPSTF criteria did (Tables 1–3). Notably, the absolute number of overdiagnosed cancers was 18.5–45.9% higher (CMR = 4.1–56.0%) than that of the USPSTF criteria. This is primarily due to risk-based-screening eligibility increasing with age (Supplementary Figure 9, available online) because cancers screen detected at older ages are more likely to be overdiagnosed. Additionally, the average age at first screening eligibility was 5–10 years higher than that of the USPSTF criteria, and it increased for higher risk thresholds (Supplementary Figure 12A, available online). Consequently, screen-detected overdiagnosis rates increased for higher risk thresholds (Supplementary Figure 12B, available online). In contrast, absolute numbers of overdiagnosed cancers decreased with increasing risk thresholds (Supplementary Figure 12C, available online). This is because at higher risk thresholds, fewer individuals are screened, reducing the overall number of screen-detected cancers.

CISNET Model Variability

Supplementary Tables 9–12 (available online) show individual CISNET model predictions for the Bach-based strategies in Table 1. The Erasmus and Michigan models estimated higher reductions in lung cancer mortality (11.0–22.7%) than the Massachusetts General Hospital (MGH) and Stanford models did (6.1–12.3%). However, the number of life-years gained per lung cancer deaths prevented was generally similar across the

Table 1. Benefits and harms of the USPSTF criteria and selected Bach model screening strategies (screening age 55–80 y) compared with no screening*

Strategy description	Corresponding risk threshold, %	Percentage ever screened, % (CMR†)	Number of CT screens per 100 000 (CMR)	Lung cancer deaths prevented per 100 000 (CMR)	Lung cancer mortality reduction, % (CMR)	Life-years gained per 100 000 (CMR)	Life-years gained per lung cancer death prevented (CMR)	Number of overdiagnosed lung cancers per 100 000 (CMR)	Percentage of screen-detected cases overdiagnosed, % (CMR)	Average number of screens per lung cancer death avoided (CMR)	Average number of screens per life-year gained (CMR)	Average number of screens per person screened (CMR)	Average age at first screening (CMR), y
USPSTF criteria	1.59	19.9 (18.7–21.2)	325 608 (301 659–337 726)	613 (337–865)	10.8 (6.7–16.9)	8590 (4665–11 922)	14.0 (13.0–15.3)	115 (49–156)	7.3 (5.3–10.4)	533 (385–1003)	38 (28–72)	16 (16–18)	55.6 (55.0–56.0)
Similar proportion of individuals selected as the USPSTF criteria's in the PLCO control arm		32.0 (30.2–33.7)	518 033 (483 152–533 542)	846 (502–1161)	15.0 (10.0–22.7)	11 195 (6432–15 198)	13.2 (12.4–14.5)	168 (77–219)	7.6 (5.6–10.5)	612 (460–1057)	46 (35–82)	16 (16–18)	61.3 (61.1–61.8)
Similar sensitivity as the USPSTF criteria's in the PLCO control arm	1.91	29.7 (28.0–31.2)	457 912 (426 885–471 544)	808 (463–1121)	14.3 (9.2–21.9)	10 533 (5830–14 293)	13.0 (12.2–14.2)	164 (72–216)	7.7 (5.7–10.4)	567 (421–1014)	43 (32–81)	15 (15–17)	62.1 (61.8–62.7)
Similar CT screens required as the USPSTF criteria's	2.80	24.2 (22.8–25.5)	323 137 (300 767–333 458)	693 (364–976)	12.2 (7.3–19.1)	8660 (4384–11 914)	12.5 (11.8–13.6)	149 (60–201)	7.8 (6.0–10.1)	466 (341–915)	37 (27–76)	13 (13–15)	64.3 (64.0–65.0)
Similar life-years deaths averted as the USPSTF criteria's	3.40	21.0 (19.8–22.1)	253 997 (236 096–263 459)	621 (303–891)	10.9 (6.1–17.4)	7491 (3529–10 330)	12.1 (11.4–13.0)	139 (52–190)	7.9 (6.1–9.7)	409 (293–869)	34 (25–75)	12 (12–13)	65.7 (65.4–66.4)
Similar life-years gained as the USPSTF criteria's	2.80	24.2 (22.8–25.5)	323 137 (300 767–333 458)	693 (364–976)	12.2 (7.3–19.1)	8660 (4384–11 914)	12.5 (11.8–13.6)	149 (60–201)	7.8 (6.0–10.1)	466 (341–915)	37 (27–76)	13 (13–15)	64.3 (64.0–65.0)

*Results are per 100 000 individuals alive at age 45 years. Lung cancer incidence in the no-screening strategy group was 7116 (6518–8 450) per 100 000 persons. Lung cancer mortality was 5670 (5010–7114) per 100 000 persons.

†All results were summarized as the mean across the four CISNET models. The numbers in parentheses denote the lower and upper range of the results across the four CISNET models.

CISNET = Cancer Intervention and Surveillance Modeling Network; CMR = CISNET model range; CT = computed tomography; PLCO = Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; USPSTF = United States Preventive Services Task Force.

Table 2. Benefits and harms of the USPSTF criteria and selected PLCOm2012 model screening strategies (screening age 55–80 y) compared with no screening*

Strategy description	Corresponding risk threshold, %	Percentage ever screened, % (CMR†)	Number of CT screens per 100 000 (CMR)	Lung cancer deaths prevented per 100 000 (CMR)	Lung cancer mortality reduction, % (CMR)	Life-years gained per 100 000 (CMR)	Life-years lung cancer death prevented (CMR)	Life-years gained per lung cancer death prevented (CMR)	Number of overdiagnosed lung cancers per 100 000 (CMR)	Percentage of screen-detected cases overdiagnosed, % (CMR)	Average number of screens per lung cancer death avoided (CMR)	Average number of screens per life-year gained (CMR)	Average number of screens per person screened (CMR)	Average age at first screening (CMR), y
USPSTF criteria	1.36	19.9 (18.7–21.2)	326 608 (301 659–337 726)	613 (337–865)	10.8 (6.7–16.9)	8590 (4665–11 922)	14.0 (13.0–15.3)	115 (49–156)	7.3 (5.3–10.4)	533 (385–1003)	38 (28–72)	16 (16–18)	55.6 (55.0–56.0)	
Similar proportion of individuals selected as the USPSTF criteria in the PLCO control arm	1.83	26.0 (24.5–27.4)	404 369 (373 609–425 538)	767 (415–1087)	13.5 (8.3–21.3)	10 054 (5210–13 679)	13.1 (12.4–14.2)	155 (65–210)	7.7 (5.7–10.5)	527 (391–996)	40 (30–79)	16 (15–17)	61.9 (61.3–62.7)	
Similar sensitivity as the USPSTF criteria in the PLCO control arm	1.70	21.8 (20.6–23.0)	307 024 (285 227–317 428)	679 (344–966)	12.0 (6.9–18.9)	8582 (4201–11 816)	12.6 (11.9–13.6)	145 (57–197)	7.8 (5.9–10.2)	452 (328–922)	36 (26–76)	14 (13–15)	63.6 (63.3–64.3)	
Similar CT screens required as the USPSTF criteria	2.20	22.9 (21.6–24.1)	329 489 (306 636–340 669)	698 (361–985)	12.3 (7.2–19.3)	8862 (4442–12 163)	12.7 (11.9–13.7)	147 (59–200)	7.7 (5.8–10.2)	472 (344–943)	37 (27–77)	14 (14–16)	63.2 (63.0–63.9)	
Similar lung cancer deaths averted as the USPSTF criteria	1.83	19.4 (18.3–20.4)	252 421 (234 634–262 394)	615 (297–882)	10.8 (5.9–17.2)	7516 (3501–10 430)	12.2 (11.5–13.2)	136 (51–186)	7.9 (6.0–10.1)	411 (294–883)	34 (24–75)	13 (12–14)	64.8 (64.5–65.5)	
Similar life-years gained as the USPSTF criteria	1.83	21.8 (20.6–23.0)	307 024 (285 227–317 428)	679 (344–966)	12.0 (6.9–18.9)	8582 (4201–11 816)	12.6 (11.9–13.6)	145 (57–197)	7.8 (5.9–10.2)	452 (328–922)	36 (26–76)	14 (13–15)	63.6 (63.3–64.3)	

*Results are per 100 000 individuals alive at age 45 years. Lung cancer incidence in the no-screening strategy group was 7116 (6518–8450) per 100 000 persons; lung cancer mortality was 5670 (5010–7114) per 100 000 persons.

†All results were summarized as the mean across the four CISNET models. The numbers in parentheses denote the lower and upper range of the results across the four CISNET models.

CISNET = Cancer Intervention and Surveillance Modeling Network; CMR = CISNET model range; CT = computed tomography; PLCO = Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; USPSTF = United States Preventive Services Task Force.

Table 3. Benefits and harms of the USPSTF criteria and selected LCDRAT model screening strategies (screening age 55–80 y) compared with no screening

Strategy description	Corresponding risk threshold, %	Percentage ever screened, % (CMR†)	Number of CT screens per 100 000 (CMR)	Lung cancer deaths prevented per 100 000 (CMR)	Lung cancer mortality reduction, % (CMR)	Life-years gained per 100 000 (CMR)	Life-years per lung cancer death prevented (CMR)	Number of overdiagnosed lung cancers per 100 000 (CMR)	Percentage of screen-detected cases % (CMR)	Average number of screens per lung cancer death avoided (CMR)	Average number of screens per life year gained (CMR)	Average number of screens per person screened (CMR)	Average age at first screening (CMR), y
USPSTF criteria	0.96	19.9 (18.7–21.2)	326 608 (301 659–337 726)	613 (337–865)	10.8 (6.7–16.9)	8590 (4665–11 922)	14.0 (13.0–15.3)	115 (49–156)	7.3 (5.3–10.4)	533 (385–1003)	38 (28–72)	1.6 (1.6–1.8)	55.6 (55.0–56.0)
Similar proportion of individuals selected as the USPSTF criteria in the PLCO control arm	1.34	33.4 (31.6–35.1)	501 689 (468 648–517 665)	844 (493–1 151)	14.9 (9.8–22.5)	11 018 (6298–14 955)	13.0 (12.4–14.3)	168 (77–220)	7.7 (5.6–10.6)	594 (450–1041)	46 (34–81)	1.5 (1.4–1.6)	62.9 (62.3–64.4)
Similar sensitivity as the USPSTF criteria in the PLCO control arm	1.70	26.4 (24.9–27.8)	394 238 (368 077–406 682)	766 (418–1 060)	13.5 (8.3–20.7)	9734 (5145–13 380)	12.7 (12.1–13.9)	157 (68–210)	7.8 (5.8–10.4)	515 (384–968)	41 (30–79)	1.5 (1.4–1.6)	62.5 (62.1–63.9)
Similar CT screens required as the USPSTF criteria	2.10	23.6 (22.3–24.9)	325 056 (303 273–336 570)	696 (366–977)	12.3 (7.3–19.1)	8631 (4365–11 838)	12.4 (11.8–13.5)	150 (60–201)	7.8 (6.0–10.0)	467 (343–917)	38 (27–77)	1.4 (1.3–1.5)	63.7 (63.2–65.0)
Similar lung cancer deaths averted as the USPSTF criteria	1.70	20.9 (19.8–22.1)	259 582 (242 052–270 053)	619 (310–885)	10.9 (6.1–17.3)	7438 (3574–10 184)	12.0 (11.4–13.1)	140 (53–190)	7.9 (6.2–9.8)	419 (302–868)	35 (25–75)	1.2 (1.2–1.4)	65.2 (64.6–66.5)
Similar life-years gained as the USPSTF criteria	1.70	23.6 (22.3–24.9)	325 056 (303 273–336 570)	696 (366–977)	12.3 (7.3–19.1)	8631 (4365–11 838)	12.4 (11.8–13.5)	150 (60–201)	7.8 (6.0–10.0)	467 (343–917)	38 (27–77)	1.4 (1.3–1.5)	63.7 (63.2–65.0)

†Results are per 100 000 individuals alive at age 45 years. Lung cancer incidence in the no-screening strategy group was 7116 (6518–8450) per 100 000 persons. Lung cancer mortality was 5670 (5010–7114) per 100 000 persons. ††Results were summarized as the mean across the four CISNET models. The numbers in parentheses denote the lower and upper range of the results across the four CISNET models. CISNET = Cancer Intervention and Surveillance Modeling Network; CMR = CISNET model range; LCDRAT = Lung Cancer Death Risk Assessment Tool; PLCO = Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; USPSTF = United States Preventive Services Task Force.

Erasmus, MGH, and Stanford models. The Michigan model estimated 1–2 more life-years gained per lung cancer death prevented compared with the other models because of allowing screening to extend lung cancer survival without averting lung cancer death.

Stanford and Michigan had the lowest screen-detected overdiagnosis rates (5.3–6.5%), whereas Erasmus and MGH had the highest rates (8.1–10.5%). However, despite having the highest overdiagnosis rate, MGH had the lowest absolute number of overdiagnosed cancers, which were due to fewer cancers being screen detected, compared with the other models. Whereas Erasmus, Stanford, and Michigan estimate the overdiagnosis rate of screen-detected cases increases with increasing risk thresholds, MGH estimates this proportion decreases. This may be due to differences in the definition of screen detection between CISNET models: In contrast to the other models, the MGH model does not consider cancers causing a positive screening result but not detected until the follow-up scan resulting from the positive screening result to be screen detected.

Overall, similarly to previous comparative-model analyses, absolute numbers of benefits and harms varied across models. However, relative performance of risk-based strategies compared with that of the USPSTF criteria was consistent across models. Similar results were found for the PLCom2012 and LCDRAT models (data not shown).

Performance by Screening Starting and Stopping Ages

When comparing selected risk-based strategies to the USPSTF criteria for screening stopping ages of 77 and 75 years, their comparative effectiveness was similar to stopping at age 80 years (data not shown). However, risk thresholds corresponding to selected outcomes differed slightly across stopping ages. Furthermore, younger screening stopping ages decreased both the proportion and absolute number of screen-detected lung cancers that were overdiagnosed.

Supplementary Figure 13 (available online) describes the effect of lowering the screening starting age to 45 years. Lowering the starting age averted more lung cancer deaths and yielded more life-years gained at relatively low risk thresholds (**Supplementary Figure 13, A and B**, available online). However, differences between starting ages decreased rapidly for increasing risk thresholds. Furthermore, younger starting ages substantially increased screens required at lower risk thresholds (5.1–13.4% at a 0.9% risk threshold, **Supplementary Figure 13C**, available online).

Accounting for Limited Life Expectancy

Table 4 compares selected PLCom2012-based strategies screening between ages 55 and 80 years to the USPSTF criteria when applying hypothetical perfect life-expectancy assessments that excluded individuals with limited life expectancies (<5 years). This reduced the absolute number of overdiagnosed lung cancers by 65.1–67.3% (CMR = 42.5–82.0%) for both USPSTF criteria and risk-based strategies. Furthermore, reductions in life-years gained were negligible (USPSTF criteria = 0.1%; CMR = –0.8 to +1.2%; risk-based strategies = –1.9% to –0.3%; CMR = –3.0% to 0.3%). Whereas lung cancer deaths averted were slightly reduced (USPSTF criteria = –4.4%; CMR = –3.2% to –7.9%; risk-based strategies = –4.5% to –6.3%; CMR = –3.0% to –9.4%), reductions in screens were greater (USPSTF criteria = –9.1%; CMR = –8.3% to –10.5%; risk-based strategies = –9.8% to

–12.9%; CMR = –9.3% to –15.1%). Consequently, accounting for limited life expectancy yielded greater improvements in efficiency for risk-based strategies than the USPSTF criteria did. Results for Bach- and LCDRAT-based strategies were similar (data not shown).

1960 Birth Cohort

Risk-based-screening strategies were also more efficient than the USPSTF criteria was in the 1960 birth cohort, as shown for selected LCDRAT-based strategies in **Table 5**. Compared with the 1950 birth cohort, lung cancer incidence and mortality in the absence of screening both were lower (17.5% and 18.1%, respectively) because of reduced smoking behavior. Consequently, the proportion of ever-eligible individuals for the USPSTF criteria decreased from 19.9% to 13.8% (30.7% lower), whereas risk-based-screening eligibility decreased by 15.6–21.1%.

As a result, absolute benefits were lower: Lung cancer deaths averted decreased by 36.9% for the USPSTF criteria and 31.2–33.0% for the selected risk-based strategies, whereas life-years gained decreased by 37.7% for the USPSTF criteria and 30.3–32.5% for the selected risk-based strategies. Similarly, absolute harms were lower: CT screens required decreased by 30.2% for the USPSTF criteria and 18.1–22.7% for the selected risk-based strategies, whereas the absolute number of overdiagnosed cases decreased by 38.3% for the USPSTF criteria and 33.3–35.7% for the selected risk-based strategies.

The average age at first screening was 1 year older for the USPSTF criteria and 0.4–1.0 years older for the selected risk-based strategies because of differences in smoking behaviors. However, overall life expectancy was also higher. Consequently, life-years gained per lung cancer death prevented were similar (0.2 fewer for the USPSTF criteria, +0.1–0.2 life-years for the selected risk-based strategies), and overdiagnosis rates of screen-detected cases decreased by 2.7% for the USPSTF criteria and 3.8–5.1% for the selected risk-based strategies.

The relative efficiency of risk-based-screening strategies (given the selected risk thresholds) compared with the USPSTF criteria was somewhat reduced compared with the 1950 birth cohort. Whereas selected risk-based-screening strategies required –21.4% to +11.4% screens per lung cancer death averted compared with the USPSTF criteria in the 1950 birth cohort, this was –17.9% to +20.2% in the 1960 birth cohort. Similarly, selected risk-based-screening strategies required –7.9% to +21.1% screens per life-year gained compared with the USPSTF criteria in the 1950 birth cohort, whereas this was –7.0% to +25.6% in the 1960 birth cohort. However, selected risk-based-screening strategies were still more efficient than the USPSTF criteria was. Results for the Bach- and PLCom2012-based strategies were similar (data not shown).

Discussion

This study shows that risk-based strategies reduced lung cancer mortality more effectively and efficiently than current USPSTF criteria did. However, though comparing favorably, risk-based strategies yielded modest additional life-years over the USPSTF criteria. Consequently, risk-based strategies prevented more lung cancer deaths but yielded fewer life-years per death prevented compared with the USPSTF criteria results. This is largely due to such strategies screening individuals at older

Table 4. Benefits and harms of the USPSTF criteria and selected PLCOm2012 model screening strategies with a hypothetical life-expectancy assessment (screening age 55–80 y) compared with no screening*

Strategy description	Corresponding risk threshold, %	Percentage ever screened, % (CMR†)	Number of CT screens per 100 000 (CMR)	Lung cancer deaths prevented per 100 000 (CMR)	Lung cancer mortality reduction, % (CMR)	Life-years gained per 100 000 (CMR)	Life-years gained per lung cancer death prevented (CMR)	Number of overdiagnosed lung cancers per 100 000 (CMR)	Percentage of screen-detected cases overdiagnosed, % (CMR)	Average number of screens per lung cancer death avoided (CMR)	Average number of screens per life-year gained (CMR)	Average number of screens per person screened (CMR)	Average age at first screening (CMR), y
USPSTF criteria	1.36	19.1 (18.0–20.3) 24.6 (22.9–26.9)	297 036 (269 853–308 570) 357 735 (326 256–372 335)	586 (322–837) 720 (393–1038)	10.3 (6.4–16.4) 12.7 (7.8–20.3)	8602 (4648–12 066) 9861 (5186–13 418)	14.7 (13.4–16.1) 13.7 (12.6–15.0)	39 (20–61) 52 (30–81)	3.2 (1.3–6.5) 3.3 (1.5–6.3)	507 (365–959) 497 (359–944)	35 (25–66) 36 (27–72)	16 (15–17) 15 (14–16)	55.7 (55.7–55.8) 61.7 (61.6–61.9)
Similar proportion of individuals selected as the USPSTF criteria's in the PLCO control arm	1.83	20.6 (19.0–22.8)	270 445 (245 877–281 949)	641 (325–929)	11.3 (6.5–18.2)	8498 (4181–11 744)	13.3 (12.2–14.4)	48 (28–75)	3.2 (1.5–5.7)	422 (303–867)	32 (23–67)	13 (12–15)	63.2 (63.1–63.5)
Similar CT screens required as the USPSTF criteria's	1.70	21.6 (20.0–23.9)	291 528 (265 273–303 765)	655 (342–951)	11.6 (6.8–18.6)	8807 (4421–12 131)	13.4 (12.3–14.8)	49 (29–76)	3.3 (1.5–5.8)	445 (319–888)	33 (24–69)	14 (13–15)	62.9 (62.7–63.1)
Similar lung cancer deaths averted as the USPSTF criteria's	2.20	18.2 (16.7–20.3)	220 749 (200 188–231 189)	579 (281–851)	10.2 (5.6–18.6)	7481 (3484–10 428)	12.9 (11.9–14.1)	45 (24–71)	3.2 (1.6–5.3)	381 (271–824)	30 (21–66)	12 (11–14)	64.4 (64.2–64.6)
Similar life-years gained as the USPSTF criteria's	1.83	20.6 (19.0–22.8)	270 445 (245 877–281 949)	641 (325–929)	11.3 (6.5–18.2)	8498 (4181–11 744)	13.3 (12.2–14.4)	48 (28–75)	3.2 (1.5–5.7)	422 (303–867)	32 (23–67)	13 (12–15)	63.2 (63.1–63.5)

*Results are per 100 000 individuals alive at age 45 years. Lung cancer incidence in the no-screening strategy group was 7116 (6518–8450) per 100 000 persons; lung cancer mortality was 5670 (5010–7114) per 100 000 persons.

†All results were summarized as the mean across the four CISNET models. The numbers in parentheses denote the lower and upper range of the results across the four CISNET models.

CISNET = Cancer Intervention and Surveillance Modeling Network; CMR = Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; USPSTF = United States Preventive Services Task Force.

Table 5. Benefits and harms of the USPSTF criteria and selected LCDRAT model screening strategies (screening age 55–80 y) in a 1960 cohort

Strategy description	Corresponding risk threshold, %	Percentage ever screened, % (CMR†)	Number of CT screens per 100 000 (CMR)	Lung cancer deaths prevented per 100 000 (CMR)	Lung cancer mortality reduction, % (CMR)	Life-years gained per 100 000 (CMR)	Life-years lung cancer death prevented (CMR)	Number of overdiagnosed lung cancers per 100 000 (CMR)	Percentage of screen-detected cases overdiagnosed, % (CMR)	Average number of screens per lung cancer death avoided (CMR)	Average number of screens per life-year gained (CMR)	Average number of screens per person screened (CMR)	Average age at first screening (CMR), y
USPSTF criteria	0.96	13.8 (12.8–14.3) 28.2 (26.3–28.9)	227 823 (225 769–229 664) 411 064 (409 654–412 742)	387 (204–587) 581 (346–853)	8.3 (5.1–13.2) 12.5 (8.6–19.2)	5352 (2822–7736) 7680 (4441–10 638)	13.8 (13.2–15.6) 13.2 (12.5–14.7)	71 (29–101) 112 (52–155)	7.1 (5.2–10.4) 7.4 (5.4–10.3)	588 (386–1124) 707 (484–1189)	43 (29–82) 54 (39–94)	16 (16–18) 15 (14–16)	56.6 (56.2–57.6) 63.7 (63.2–65.1)
Similar proportion of individuals selected as the USPSTF criteria's in the PLCO control arm	1.34	21.8 (20.3–22.4)	313 782 (313 165–314 698)	520 (289–776)	11.2 (7.2–17.4)	6660 (3552–9416)	12.8 (12.1–14.2)	103 (45–143)	7.4 (5.5–10.1)	604 (406–1086)	47 (33–89)	14 (14–15)	63.4 (63.0–64.7)
Similar CT screens required as the USPSTF criteria's	1.70	19.0 (17.7–19.5)	254 053 (253 337–254 860)	471 (248–712)	10.1 (6.2–16.0)	5880 (2926–8453)	12.5 (11.8–13.8)	97 (40–137)	7.5 (5.7–9.8)	540 (358–1027)	43 (30–88)	13 (13–14)	64.4 (63.9–65.6)
Similar lung cancer deaths averted as the USPSTF criteria's	2.10	16.5 (15.4–17.0)	200 646 (199 830–202 045)	415 (211–630)	8.9 (5.3–14.1)	5020 (2404–7234)	12.1 (11.4–13.4)	90 (35–127)	7.6 (5.9–9.6)	483 (319–957)	40 (28–84)	12 (12–13)	65.6 (65.2–66.8)
Similar life-years gained as the USPSTF criteria's	1.70	19.0 (17.7–19.5)	254 053 (253 337–254 860)	471 (248–712)	10.1 (6.2–16.0)	5880 (2926–8453)	12.5 (11.8–13.8)	97 (40–137)	7.5 (5.7–9.8)	540 (358–1027)	43 (30–88)	13 (13–14)	64.4 (63.9–65.6)

*Results are per 100 000 individuals alive at age 45 years. Lung cancer incidence in the no-screening strategy group was 5870 (5278–6752) per 100 000 persons; lung cancer mortality was 4643 (4016–5307) per 100 000 persons.

†All results were summarized as the mean across the four CISNET models. The numbers in parentheses denote the lower and upper range of the results across the four CISNET models.

CISNET = Cancer Intervention and Surveillance Modeling Network; CMR = CISNET model range; CT = computed tomography; LCDRAT = Lung Cancer Death Risk Assessment Tool; PLCO = Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; USPSTF = United States Preventive Services Task Force.

ages than in the USPSTF criteria, when lung cancer and competing mortality risks both are highest.

Analogously, risk-based strategies increased overdiagnosis compared with the USPSTF criteria results. Higher risk thresholds for screening eligibility lowered overall numbers of screen-detected and overdiagnosed cases, but simultaneously increased screen-detected overdiagnosis. Applying high risk thresholds predominantly selects older individuals and those with greater smoking exposures, who are more likely to attain the required risk level (12,24,34). However, these risk factors are also associated with higher overall mortality, making these individuals more susceptible to competing mortality and overdiagnosis (13,35). Thus, the risk threshold and the screening stopping age should both be explicitly considered for optimal risk-based-screening strategies.

Screening benefits and harms were similar across risk-prediction models for risk thresholds matching the USPSTF criteria's required CT screens, lung cancer deaths averted, or life-years gained. However, the full PLCom2012 and LCDRAT models include more covariates, which may improve risk assessments in individuals with nonsmoking risk factors.

Previous studies evaluated risk-prediction models in retrospective analyses of trials and cohorts (5,6,10). These studies proposed risk thresholds based on improved performance over that of the USPSTF criteria, but considered limited timeframes (eg, 6 years). Our natural history-model approach allows evaluating lifetime screening benefits and harms, such as screening-extended lung cancer survival and overdiagnosis. In addition, the natural history models incorporate differences in CT screening effectiveness between different lung cancer histologies. Our study indicates risk-threshold performance differs over longer timeframes. Furthermore, risk thresholds performing well within retrospective analyses of trials and/or cohorts may be inefficient when applied in population-based screening programs. Our findings are in agreement with a recent NLST-based study, suggesting risk-based selection reduces lung cancer mortality more efficiently than the USPSTF criteria does, but it modestly improves life-years gained (15). However, although this study focused on risk-decile differences within NLST, we evaluated the long-term effects of risk-based strategies with different risk-prediction models, risk thresholds, and screening starting and stopping ages in the general population.

This study has some limitations. First, only age, sex, and smoking-related risk factors are considered, for both natural history models and evaluated risk-prediction models. Yet, risk factors such as COPD increase both lung cancer and other-cause mortality risks (3,14). However, risk-prediction models have shown improved discrimination, calibration, and net benefit over the USPSTF criteria when using only smoking-related risk factors (5). Moreover, the natural history models have been shown to reproduce observed lung cancer outcomes for the US general population (years 1965–2010) and the NLST and PLCO trials (29,31–33,36,37). Furthermore, the risk-profile simulator (SHG) accounts for increased other-cause mortality risk that is due to smoking (13,22). Additionally, previous studies indicate the truncated PLCom2012 model had good discrimination and calibration (5). However, excluding nonsmoking risk factors may underestimate risk for individuals with nonsmoking risk factors. This is of particular importance among risk groups with lower smoking exposures, for whom nonsmoking risk factors have a comparatively greater influence on lung cancer risk. Therefore, future work should explore the effect of considering additional risk factors in risk-based strategies.

Second, a single 1950 birth cohort was evaluated, similar to our analyses that informed the USPSTF (19). However, we performed sensitivity analyses for a 1960 birth cohort. Both USPSTF criteria and risk-based-screening eligibility were lower because of lower smoking prevalence and average smoking intensity, compared with older birth cohorts (13,28,38). Although risk-based strategies were still more efficient than the USPSTF criteria were, absolute benefits and harms were lower compared with the 1950 birth cohort. Furthermore, risk thresholds corresponding to specific metrics of the USPSTF criteria differed between birth cohorts. Thus, risk-based-screening performance in younger birth cohorts requires further evaluation.

Third, absolute numbers of benefits and harms varied across CISNET models. This reflects differences in assumptions and model structures (19,35). Nonetheless, the effectiveness of risk-based strategies compared with that of the USPSTF criteria was similar across models.

Risk-based-screening cost-effectiveness remains uncertain. NLST-based economic evaluation indicates risk-based selection could greatly improve screening cost-effectiveness (39). However, another study suggests modest improvements in cost effectiveness because of high-risk individuals having higher screening-related costs (15). Our study suggests additional aspects for consideration. Risk-based strategies yielding similar life-years as the USPSTF criteria outcomes required 0–6% fewer screens. Cost-effectiveness studies suggest CT costs considerably influence lung cancer screening cost effectiveness and budget impact (34,40). Even modest reductions in CT examinations would improve both. In addition, risk-based strategies yielding similar life-years as that of the USPSTF criteria averted 10.8–13.5% more lung cancer deaths. The costs of care, particularly in the terminal phase, have been shown to have major effects on cost-effectiveness (40). Therefore, risk-based screening could yield lower costs of care compared with the USPSTF criteria. However, risk-based strategies screen older individuals, with more comorbidities potentially affecting quality of life, compared with the USPSTF criteria (15). Thus, risk-based strategies yielding similar life-years as the USPSTF criteria yields may have fewer quality-adjusted life-years. Furthermore, risk-based strategies yielding similar life-years as the USPSTF criteria had 25.9–30.1% more overdiagnosed cases, negatively affecting quality of life, and incurring unnecessary treatment costs. Thus, careful analysis of the cost-effectiveness of risk-based screening is essential.

Risk-based-screening (cost-)effectiveness may be improved by reducing overdiagnosis. Augmenting lung cancer risk estimates with life-expectancy information may allow personalized overdiagnosis risk assessments. A recent study showed good performance for predicting 5-year all-cause mortality risk (41). This would be valuable in aiding informed decision making on screening participation and personalizing screening stopping ages. Our sensitivity analyses support this, suggesting accurately accounting for life expectancies of fewer than 5 years retains the life-years gained by screening, while reducing overdiagnosis by more than 65.3%.

Implementing population-based risk-based screening has potential barriers. For example, whereas risk factors such as COPD could be derived from linked medical records, others may not be. Although this may improve risk assessments for individuals with nonsmoking risk factors, acquiring additional information might be a barrier for primary care implementation.

In conclusion, risk-based screening reduces lung cancer mortality more effectively and efficiently compared with current USPSTF recommendations. However, risk-based screening

modestly improves life-years gained and increases overdiagnosis. Future studies should investigate the cost-effectiveness of risk-based screening and the potential for reducing overdiagnosis in high-risk individuals.

Funding

This report is based on research conducted by the National Cancer Institute's (NCI's) CISNET Lung Consortium (NCI grant U01-CA199284).

Notes

Affiliations of authors: Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, Zuid-Holland, the Netherlands (KtH, EFB, HJdK); Department of Radiology, Stanford University, Palo Alto, CA (MB, IT, SSH, SKP); Department of Epidemiology, University of Michigan, Ann Arbor, MI (PC, JJ, RM); Department of Medicine, Stanford University, Palo Alto, CA (SSH); Harvard Medical School, Boston, MA (CYK); Department of Radiology, Massachusetts General Hospital, Boston, MA (CYK); Department of Health Sciences, Brock University, St. Catharines, ON, Canada (MCT); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (EJF).

The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; or the decision to submit the manuscript for publication. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCI. The statements contained herein are solely those of the authors and do not represent or imply concurrence or endorsement by the National Cancer Institute.

HJdK is the principal investigator of the Dutch-Belgian Lung Cancer Screening Trial (Nederlands-Leuven Longkanker Screenings onderzoek; the NELSON trial). KtH and EFB are researchers affiliated with the NELSON trial. HJdK and KtH were involved in a Health Technology Assessment study for CT Lung Cancer Screening in Canada (Dr Paszat, Cancer Care Ontario). HJdK and KtH received a grant from the University of Zurich to assess the cost-effectiveness of computed tomographic lung cancer screening in Switzerland. HJdK took part in a 1-day advisory meeting on biomarkers organized by The University of Texas MD Anderson Cancer Center/Health Sciences during the 16th World Conference on Lung Cancer. KtH was an invited speaker at the 4th International Association for the Study of Lung Cancer (IASLC) Strategic Screening Advisory Committee CT Screening workshop, December 3, 2016, before the 17th IASLC World Conference on lung cancer in Vienna (2016), and an invited speaker at the 19th IASLC World Conference on lung cancer in Toronto (2018). MCT developed the PLCom2012 lung cancer risk-prediction model. The model is available free to noncommercial users. For commercial users licensing has been assigned to Brock University. To date, MCT has not received any money for use of the PLCom2012 model.

We thank the NCI for access to its data collected by the NLST and the PLCO. We thank the staff of Information Management Services for assistance with the harmonization of the NLST and PLCO datasets. Furthermore, we would like to thank the NLST and PLCO study participants for their contributions to these studies. Finally, we would like to thank L. Cheung and H. A.

Katki for providing and allowing use of the constrained LCDRAT model for these analyses.

References

- Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med*. 2011;365(5):395–409.
- Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2014;160(5):330–338.
- Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. *N Engl J Med*. 2013;368(8):728–736.
- Raji OY, Duffy SW, Agbaje OF, et al. Predictive accuracy of the Liverpool lung project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. *Ann Intern Med*. 2012;157(4):242–250.
- ten Haaf K, Jeon J, Tammemägi MC, et al. Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. *PLoS Med*. 2017;14(4):e1002277.
- Katki HA, Kovalchik SA, Petito LC, et al. Implications of nine risk prediction models for selecting ever-smokers for computed tomography lung cancer screening. *Ann Intern Med*. 2018;169(1):10.
- Wood DE, Kazerooni EA, Baum SL, et al. Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2018;16(4):412–441.
- de Koning HJ, van der Aalst CM, ten Haaf K, Oudkerk M. PL02.05 Effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial. *J Thorac Oncol*. 2018;13(10):S185.
- Oudkerk M, Devaraj A, Vliegthart R, et al. European position statement on lung cancer screening. *Lancet Oncol*. 2017;18(12):e754–e766.
- Katki HA, Kovalchik SA, Berg CD, et al. Development and validation of risk models to select ever-smokers for CT lung cancer screening. *JAMA*. 2016;315(21):2300–2311.
- Tammemägi MC, Schmidt H, Martel S, et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. *Lancet Oncol*. 2017;18(11):1523–1531.
- Field JK, Duffy SW, Baldwin DR, et al. The UK lung cancer screening trial: A pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. *Health Technol Assess*. 2016;20(40):1–146.
- Holford TR, Levy DT, McKay LA, et al. Patterns of birth cohort-specific smoking histories, 1965–2009. *Am J Prev Med*. 2014;46(2):e31–e37.
- Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. *N Engl J Med*. 2013;368(4):351–364.
- Kumar V, Cohen JT, van Klaveren D, et al. Risk-targeted lung cancer screening: a cost-effectiveness analysis. *Ann Intern Med*. 2018;168(3):161–169.
- Crosbie PA, Balata H, Evison M, et al. Implementing lung cancer screening: baseline results from a community-based “Lung Health Check” pilot in deprived areas of Manchester. *Thorax*. 2019;74(4):405–409.
- Cheung LC, Katki HA, Chaturvedi AK, et al. Preventing lung cancer mortality by computed tomography screening: the effect of risk-based versus U.S. Preventive Services Task Force eligibility criteria, 2005–2015. *Ann Intern Med*. 2018;168(3):229–232.
- Duffy SW, Field JK, Allgood PC, et al. Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom. *Br J Cancer*. 2014;110(7):1834.
- de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2014;160(5):311–320.
- Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. *J Natl Cancer Inst*. 2003;95(6):470–478.
- Meza R, Hazelton WD, Colditz GA, et al. Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up studies using a multistage carcinogenesis model. *Cancer Causes Control*. 2008;19(3):317–328.
- Jeon J, Holford TR, Levy DT, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. *Ann Intern Med*. 2018;169(10):684.
- Tam J, Levy DT, Jeon J, et al. Projecting the effects of tobacco control policies in the USA through microsimulation: a study protocol. *BMJ Open*. 2018;8(3):e019169.
- Tammemägi MC, Church TR, Hocking WG, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. *PLoS Med*. 2014;11(12):e1001764.
- ten Haaf K, de Koning HJ. Should never-smokers at increased risk for lung cancer be screened? *J Thorac Oncol*. 2015;10(9):1285–1291.
- Landy R, Cheung LC, Berg CD, et al. Contemporary implications of U.S. Preventive Services Task Force and risk-based guidelines for lung cancer screening eligibility in the United States. *Ann Intern Med*. 2019;171(5):384–386.

27. Caverly TJ, Cao P, Hayward RA, et al. Identifying patients for whom lung cancer screening is preference-sensitive: a microsimulation study. *Ann Intern Med.* 2018;169(1):1–9.
28. Criss SD, Sheehan DF, Palazzo L, et al. Population impact of lung cancer screening in the United States: projections from a microsimulation model. *PLoS Med.* 2018;15(2):e1002506.
29. Han SS, Erdogan SA, Toumazis I, et al. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. *Cancer Causes Control.* 2017;28(9):947–958.
30. Lin RS, Plevritis SK. Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model. *Cancer Causes Control.* 2012;23(1):175–185.
31. McMahon PM, Kong CY, Johnson BE, et al. Chapter 9: the MGH-HMS lung cancer policy model: tobacco control versus screening. *Risk Anal.* 2012;32(suppl 1):S117–S124.
32. ten Haaf K, van Rosmalen J, de Koning HJ. Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials. *Cancer Epidemiol Biomarkers Prev.* 2015;24(1):154.
33. Meza R, ten Haaf K, Kong CY, et al. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. *Cancer* 2014;120(11):1713–1724.
34. Cressman S, Peacock SJ, Tammemägi MC, et al. The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency. *J Thorac Oncol.* 2017;12(8):1210–1222. <https://doi.org/10.1016/j.jtho.2017.04.021>.
35. Han SS, ten Haaf K, Hazelton WD, et al. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. *Int J Cancer.* 2017;140(11):2436–2443.
36. Hazelton WD, Jeon J, Meza R, et al. Chapter 8: the FHCRC lung cancer model. *Risk Anal.* 2012;32(suppl 1):S99–S116.
37. Schultz FW, Boer R, de Koning HJ. Chapter 7: description of MISCAN-lung, the Erasmus MC lung cancer microsimulation model for evaluating cancer control interventions. *Risk Anal.* 2012;32(suppl 1):S85–S98.
38. Wang Y, Midthun DE, Wampfler JA, et al. Trends in the proportion of patients with lung cancer meeting screening criteria. *JAMA.* 2015;313(8):853–855.
39. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. *N Engl J Med.* 2014;371(19):1793–1802.
40. ten Haaf K, Tammemägi MC, Bondy SJ, et al. Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a microsimulation modeling analysis in Ontario, Canada. *PLoS Med.* 2017;14(2):e1002225.
41. Manuel DG, Perez R, Sanmartin C, et al. Measuring burden of unhealthy behaviours using a multivariable predictive approach: life expectancy lost in Canada attributable to smoking, alcohol, physical inactivity, and diet. *PLoS Med.* 2016;13(8):e1002082.